ERBB2 and breast carcinoma: Interestingly, the “14-3-3-mediated Signaling” and “HER-2 Signaling in Breast cancer” pathways were both highly upregulated in TcdB-treated cells, while there was no regulation found for those pathways in TcdA-treated cells.